Drug profile · INN
mexiletine hydrochloride
MEXILETINE HYDROCHLORIDE
mexiletine hydrochloride (MEXILETINE HYDROCHLORIDE) is a sodium channel alpha subunit blocker. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — mexiletine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
mexiletine hydrochloride (MEXILETINE HYDROCHLORIDE) is a sodium channel alpha subunit blocker. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mexiletine hydrochloride?
mexiletine hydrochloride (MEXILETINE HYDROCHLORIDE) is a sodium channel alpha subunit blocker. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for mexiletine hydrochloride?
MEXILETINE HYDROCHLORIDE is a marketed brand name for mexiletine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mexiletine hydrochloride?
mexiletine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.